ACTIGEN

Under the trademark of ACTIGEN, Affitech AS is marketing Protein L, which binds to antibodies and antibody fragments with high specificity. A portfolio of Protein L products has been established for detection and purification of antibodies. Affitech AS (Oslo, Norway) acquired Actigen in September 2000 from Active Biotech AB (Lund, Sweden). In addition to Actigen's distribution and licence agreements, Affitech also acquired a comprehensive package of intellectual property related to Protein L previously owned by Active Biotech AB and its subsidiary, Actinova Limited (Cambrigde, UK). Affitech is a human therapeutics company with primary focus on discovery and development of antibodies for treatment of cancer and infectious diseases. Utilizing various techniques, such as phage display and high throughtput screening, Affitech has been able to obtain high affinity and specific antibodies to a variety of antigens. More information can be found on www.affitech.com.

Contact Details: Gaustadalléen 21 Oslo Oslo N-0349 Norway Tel: 47 2295 8879 Fax: 47 2295 8358 Email: silja@affitech.com or info@actigen.com WWW: www.actigen.com/

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 374 times since April 2007, the link to the organisation's website has been followed 86 times

Recent Search Terms used to find this page: Actigen established | .

Search for more companies in Oslo

Search for more companies in Oslo

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ACTIGEN